Abstract

Categorizing people with late-onset Alzheimer’s disease into biologically coherent subgroups is important for personalized medicine. We evaluated data from five studies (total n = 4050, of whom 2431 had genome-wide single-nucleotide polymorphism (SNP) data). We assigned people to cognitively defined subgroups on the basis of relative performance in memory, executive functioning, visuospatial functioning, and language at the time of Alzheimer’s disease diagnosis. We compared genotype frequencies for each subgroup to those from cognitively normal elderly controls. We focused on APOE and on SNPs with p < 10−5 and odds ratios more extreme than those previously reported for Alzheimer’s disease (<0.77 or >1.30). There was substantial variation across studies in the proportions of people in each subgroup. In each study, higher proportions of people with isolated substantial relative memory impairment had ≥1 APOE ε4 allele than any other subgroup (overall p = 1.5 × 10−27). Across subgroups, there were 33 novel suggestive loci across the genome with p < 10−5 and an extreme OR compared to controls, of which none had statistical evidence of heterogeneity and 30 had ORs in the same direction across all datasets. These data support the biological coherence of cognitively defined subgroups and nominate novel genetic loci.

Highlights

  • Clinical heterogeneity is common among people with lateonset Alzheimer’s disease

  • We previously evaluated one study’s data and showed that our strategy identified a subgroup with higher degrees of amyloid angiopathy and higher proportions with≥1 APOE ε4 allele [4]

  • The proportion who were female ranged from 51% for isolated substantial relative executive functioning impairment to 63% of those with isolated substantial relative visuospatial impairment

Read more

Summary

Introduction

Clinical heterogeneity is common among people with lateonset Alzheimer’s disease (see [1] for a review). Categorizing people with a condition into biologically coherent subgroups is an important personalized medicine strategy [2]. This strategy is recommended for neurodegenerative conditions [3]. Extended author information available on the last page of the article. Subgroups are identified, further investigations may elucidate subgroup-specific treatments. Genetic data may be useful for determining whether a proposed categorization strategy results in biologically coherent subgroups (see the Box 1)

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.